# Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From Melanoma

> **NCT04206358** · PHASE1 · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 30 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** OrienX010 combination with JS001

## Key facts

- **NCT ID:** NCT04206358
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-13
- **Primary completion:** 2021-02-27
- **Final completion:** 2023-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04206358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04206358, "Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04206358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*